Zapping cancer: trial tests electromagnetic fields with drug for tough liver tumors
NCT ID NCT04327700
Summary
This study aimed to see if adding a special electromagnetic field treatment to the cancer drug regorafenib could better control advanced liver cancer that had worsened after initial therapy. It was for patients whose cancer had progressed despite standard first-line treatments. The trial was terminated early after enrolling only 2 participants, so no conclusions could be drawn.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.